Horie K

References (6)

Title : E2027 (irsenontrine), a phosphodiesterase 9 inhibitor, enhances cholinergic function when combined with donepezil hydrochloride - Ando_2025_Eur.J.Pharmacol_1006_178126
Author(s) : Ando M , Yamazaki K , Takahashi E , Kotani S , Patel T , Bradford A , Gartlon J , Norimine Y , Horie K
Ref : European Journal of Pharmacology , 1006 :178126 , 2025
Abstract :
PubMedSearch : Ando_2025_Eur.J.Pharmacol_1006_178126
PubMedID: 40914266

Title : E2027 (irsenontrine), a phosphodiesterase 9 inhibitor, enhances cholinergic function when combined with donepezil hydrochloride - Ando_2025_Eur.J.Pharmacol_1006_178126
Author(s) : Ando M , Yamazaki K , Takahashi E , Kotani S , Patel T , Bradford A , Gartlon J , Norimine Y , Horie K
Ref : European Journal of Pharmacology , 1006 :178126 , 2025
Abstract :
PubMedSearch : Ando_2025_Eur.J.Pharmacol_1006_178126
PubMedID: 40914266

Title : E2027 (irsenontrine), a phosphodiesterase 9 inhibitor, enhances cholinergic function when combined with donepezil hydrochloride - Ando_2025_Eur.J.Pharmacol_1006_178126
Author(s) : Ando M , Yamazaki K , Takahashi E , Kotani S , Patel T , Bradford A , Gartlon J , Norimine Y , Horie K
Ref : European Journal of Pharmacology , 1006 :178126 , 2025
Abstract :
PubMedSearch : Ando_2025_Eur.J.Pharmacol_1006_178126
PubMedID: 40914266

Title : Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma -
Author(s) : Horie K , Inoue S
Ref : Oncotarget , 14 :807 , 2023
PubMedID: 37713333

Title : Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma -
Author(s) : Horie K , Inoue S
Ref : Oncotarget , 14 :807 , 2023
PubMedID: 37713333

Title : Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma -
Author(s) : Horie K , Inoue S
Ref : Oncotarget , 14 :807 , 2023
PubMedID: 37713333